StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / axcynsis.com

Axcynsis Therapeutics

Axcynsis Therapeutics (axcynsis.com): 1 change recorded in its website history since October 2022. Homepage last checked 5 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. HeadlineBetween and
    BeforeSynthesizing the X-factor
    AfterA ntibody- X C onjugate S yn the sis

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 2 October 2022

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Synthesizing the X-factor

About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. August 2023 – November 2026 · 8 captures · latest observed messagingA ntibody- X C onjugate S yn the sis

    About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta

    This wording observed 5 November 2026.

    current websiteHistorical capture not publicly available
    Inspect 8 captures in this group
    • 20 August 2023 · A ntibody- X C onjugate S yn the sis archived page
    • 26 February 2024 · A ntibody- X C onjugate S yn the sis archived page
    • 4 August 2024 · A ntibody- X C onjugate S yn the sis archived page
    • 14 February 2025 · A ntibody- X C onjugate S yn the sis archived page
    • 18 July 2025 · A ntibody- X C onjugate S yn the sis archived page
    • 18 February 2026 · A ntibody- X C onjugate S yn the sis archived page
    • 11 July 2026 · A ntibody- X C onjugate S yn the sis archived page
    • 5 November 2026 · A ntibody- X C onjugate S yn the sis current websiteHistorical capture not publicly available
  2. October 2022 – February 2023 · 2 capturesSynthesizing the X-factor

    About Us Axcynsis Therapeutics is a platform-based biotechnology company focusing on the development of Antibody-X Conjugate (AXC) therapies to revolutionise cancer treatments. Leveraging on proprieta

    This wording observed 16 February 2023.

    archived page
    Inspect 2 captures in this group

Cite this record

StartupHistory, “Axcynsis Therapeutics” company record, https://startuphistory.org/c/axcynsis.com

Machine-readable: /c/axcynsis.com.json. How changes are found: method.